OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cheah on the Safety Profile of TG-1701 With and Without Ublituximab/Umbralisib in CLL

October 20th 2021

Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.

Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLC

October 20th 2021

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

Dr. Patel on the Utility of Consolidative Durvalumab in Stage III NSCLC

October 20th 2021

Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.

Dr. Secord on the Design of the OReO Trial in Ovarian Cancer

October 19th 2021

Angeles A. Secord, MD, discusses the design of the phase 3b OReO trial in ovarian cancer.

Dr. Ailawadhi on the Rationale for Evaluating Lisaftoclax in CLL

October 19th 2021

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Dr. Soares on Advances in the Management of Pancreatic NETs

October 19th 2021

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

Dr. Zurita-Saavedra on Moving Therapies From mCRPC to mHSPC

October 19th 2021

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Weiss on the Rationale for the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

October 19th 2021

Jared Weiss, MD, discusses the rationale for the phase 1/2 KRYSTAL-1 trial in patients with KRAS G12C–mutated colorectal cancer.

Dr. Singh on the Potential Effects of Radiation Timing in Head and Neck Cancer

October 18th 2021

Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.

Dr. Subudhi on Future Directions With Immunotherapy in Prostate Cancer

October 18th 2021

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

Dr. Erba on Selecting Between Ibrutinib and Acalabrutinib in CLL

October 18th 2021

Harry Paul Erba, MD, PhD, discusses selecting between ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL

October 15th 2021

Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.

Dr. Marshall on Key Data from the DESTINY-Gastric02 Trial in HER2+ Gastric Cancer

October 15th 2021

John L. Marshall, MD, discusses key findings from the phase 2 DESTINY-Gastric02 trial examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive gastric cancer.

Dr. Johnson on Datopotamab Deruxtecan in NSCLC With Actionable Genomic Alterations

October 15th 2021

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

Dr. Mulcahy on Key Takeaways from the EPOCH Trial With TheraSphere Y-90 in CRC

October 15th 2021

Mary F. Mulcahy, MD, discusses the key takeaways from the ongoing EPOCH trial in patients with colorectal cancer and liver metastases.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL and Other Hematologic Malignancies

October 15th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

October 14th 2021

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Dr. Roychowdhury on Future Research Directions With FGFR Inhibitors in Cholangiocarcinoma

October 14th 2021

Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.

Dr. Van Tine on Next Steps With Catequentinib in Soft Tissue Sarcoma

October 14th 2021

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.

Dr. Siddiqui on the Current State of Treatment in Nonmetastatic CRPC

October 14th 2021

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.